LIVN Earnings Prediction
The chart below shows how LIVN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LIVN sees a +0.44% change in stock price 10 days leading up to the earnings, and a -2.55% change 10 days following the report. On the earnings day itself, the stock moves by +0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
LIVN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
318.12M
11.19%
-0.14%
Gross Margin
70.81%
0.40%
3.07%
Operating Margin
14.09%
123.30%
-0.21%
Net Margin
10.36%
504.69%
101.95%
EPS
0.60
528.57%
100.00%
No Data Available
LIVN Earnings Analysis
LivaNova PLC Ordinary Shares Corporation (LIVN.O) Earnings Conference Call
Positive
Sustained Revenue Increase: 1. Consistent Revenue Growth: LivaNova achieved an 11% revenue increase in Q3 2024, marking the seventh consecutive quarter of double-digit growth, with 12% organic revenue growth year-to-date.
Cardiopulmonary Segment Growth: 2. Strong Performance in Cardiopulmonary Segment: The cardiopulmonary segment reported revenue of $172 million, a 15% increase compared to Q3 2023, driven by over 20% growth in heart-lung machine revenue due to the successful Essenz launch.
Market Share Expansion: 3. Increased Market Share: The company's oxygenator market share grew from the low 30s in early 2023 to the mid-30s, contributing over 100 basis points of growth year-to-date, supported by strong demand and effective pricing strategies.
Operating Margin Improvement: 4. Improved Operating Margins: Adjusted operating income increased to $64 million, with an operating margin of 20%, up from 16% in Q3 2023, driven by higher revenue and improved operating leverage.
Free Cash Flow Increase: 5. Significant Free Cash Flow Generation: LivaNova reported adjusted free cash flow of $47 million for the quarter, up from $26 million in the prior year, reflecting stronger operating results and working capital improvements.
Negative
Rising Debt Levels: 1. Increased Debt Levels: Total debt rose to $626 million from $587 million at year-end 2023, driven by a $345 million private offering of convertible senior notes and the repurchase of $230 million of convertible senior notes.
R&D Investment Increase: 2. R&D Expense Growth: Adjusted R&D expense increased to $47 million in Q3 2024 from $42 million in Q3 2023, indicating a rise in investment without a corresponding revenue increase in the same segment.
Rising Effective Tax Rate: 3. Higher Effective Tax Rate: The adjusted effective tax rate increased to 23% in Q3 2024 from 10% in Q3 2023, with expectations of a further rise to 24%-25% in 2025, impacting future earnings.
European Epilepsy Revenue Decline: 4. Decline in European Epilepsy Revenue: Epilepsy revenue in Europe and Rest of World grew only 3% year-over-year, with a noted decline in Europe, contrasting with double-digit growth in the Rest of World.
Revenue Growth Slowdown: 5. Projected Slowdown in Revenue Growth: The company anticipates a slowdown in revenue growth for Q4 2024 due to strong performance comparisons from Q4 2023, despite overall positive market conditions.
LIVN FAQs
How does LIVN typically perform around its earnings report dates?
Is LivaNova PLC (LIVN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LIVN Earning Call Sentiment
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LIVN.O
1.71%Positive
The earnings call summary shows strong financial performance with a revenue increase of 11%, strong cardiopulmonary and epilepsy revenue growth, and improved operating income margins. The shareholder return plan includes a significant share repurchase. The Q&A session did not reveal major concerns, though there was some uncertainty about future growth expectations. Overall, the positive financial metrics and strategic initiatives suggest a positive stock price movement over the next two weeks.
